- Home
- LPCN vs BCDA Comparison
LPCN vs BCDA Comparison
Compare LPCN & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPCN
- BCDA
- Stock Information
- Founded
- LPCN 1997
- BCDA N/A
- Country
- LPCN United States
- BCDA United States
- Employees
- LPCN N/A
- BCDA N/A
- Industry
- LPCN Biotechnology: Pharmaceutical Preparations
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- LPCN Health Care
- BCDA Health Care
- Exchange
- LPCN Nasdaq
- BCDA Nasdaq
- Market Cap
- LPCN 13.8M
- BCDA 13.7M
- IPO Year
- LPCN N/A
- BCDA N/A
- Fundamental
- Price
- LPCN $3.18
- BCDA $1.37
- Analyst Decision
- LPCN Strong Buy
- BCDA Strong Buy
- Analyst Count
- LPCN 1
- BCDA 1
- Target Price
- LPCN $7.00
- BCDA $25.00
- AVG Volume (30 Days)
- LPCN 54.7K
- BCDA 92.8K
- Earning Date
- LPCN 11-06-2025
- BCDA 11-12-2025
- Dividend Yield
- LPCN N/A
- BCDA N/A
- EPS Growth
- LPCN N/A
- BCDA N/A
- EPS
- LPCN N/A
- BCDA N/A
- Revenue
- LPCN $4,322,693.00
- BCDA N/A
- Revenue This Year
- LPCN N/A
- BCDA N/A
- Revenue Next Year
- LPCN N/A
- BCDA N/A
- P/E Ratio
- LPCN N/A
- BCDA N/A
- Revenue Growth
- LPCN N/A
- BCDA N/A
- 52 Week Low
- LPCN $2.52
- BCDA $1.00
- 52 Week High
- LPCN $5.50
- BCDA $3.20
- Technical
- Relative Strength Index (RSI)
- LPCN 61.21
- BCDA 53.97
- Support Level
- LPCN $3.07
- BCDA $1.27
- Resistance Level
- LPCN $3.32
- BCDA $1.34
- Average True Range (ATR)
- LPCN 0.20
- BCDA 0.07
- MACD
- LPCN 0.06
- BCDA 0.02
- Stochastic Oscillator
- LPCN 65.82
- BCDA 100.00
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).